There are 2,514 papers on TP53 in aging research: 23 trials and 306 observational studies in people, 1,118 in animals, 749 in cells, 236 reviews. The newest story, Nov 19, 2026: “Hydrogen sulfide may ease signs of heart aging in mice”.
TP53 shortens lifespan in mice and increases senescence in human cells in experiments replicated by independent labs; other experiments show no clear lifespan effect in mice or lifespan extension in zebrafish. Some studies include company-affiliated authors, and some papers declare company ties.
538 findings in 406 papers from 1991 to 2026, 42 of them since April 2026
Independent labs found the same change in cells, mice and people. 216 independent labs in 34 countries.
“Classic LFS alleles at high VAF conferred markedly increased risk of hematological malignancy but not solid tumors”
Cells, mice and humans: replicated by independent labs. Worms or flies: a single group.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
Includes the processes named after it and trials of drugs aimed at it.
216 independent labs in 34 countries
21 findings against
Funders: National Institutes of Health and others
33 of 455 findings with company ties
Human trial23
Humans306
Animals1,099
Model organisms19
Cells749
In silico75
Interventions
45
Quercetin
↓downin human cells1↑upin human cells1
2 studies
Quercetin decreases TP53 in IL-1β-induced chondrocytes.
“decreased macrophage pro-inflammatory polarization, correlating with reduced p53 expression”
Resveratrol increases TP53 in humans (type 2 diabetes) (fold change 1.29, p = .04).
“Resveratrol supplementation significantly increased mRNA expression levels of p53 and p21 genes, compared with the placebo group (fold change of p53 = 1.29, p = .04; fold change of p21 = 1.46, p = .006).”
Human trialtype 2 diabetestrans-resveratrol1,000 mg8 weeksn = 71
TP53 extends lifespan in mice (Transgenic expression of human Δ133p53α in a heterozygous HGPS mouse model) (+11% median lifespan; 387 versus 349 days).
“extends median lifespan by 11% (387 versus 349 days, P = 0.0379).”
AnimalsTransgenic expression of human Δ133p53α in a heterozygous HGPS mouse model
TP53 mediates apoptosis in mice (initiation shown with Puma/Bbc3 tdTomato reporter mice in a p53-deficient background).
“the new reporters reliably inform on p53-dependent and p53-independent initiation of both apoptotic or cell cycle arrest/senescence programs, respectively, in vitro and in vivo”
Animalsinitiation shown with Puma/Bbc3 tdTomato reporter mice in a p53-deficient background
TP53 increases apoptosis in late-generation TERC KO mice; shown by knockout.
“additional deficiency of the tumour suppressor p53 in the Trp53-/- allele of the late generation of TERC KO mice attenuates the increased senescent and apoptotic markers significantly”
Animalsin late-generation TERC KO mice; shown by knockoutalveolar type 2 cells
TP53 inhibits senescence-associated secretory phenotype (SASP) in human cells (Restored Δ133p53 expression in near-senescent astrocytes).
“Restored expression of Δ133p53 in near-senescent, otherwise neurotoxic astrocytes conferred them with neuroprotective activity through repression of SASP and induction of neurotrophic growth factors.”
CellsRestored Δ133p53 expression in near-senescent astrocytesastrocyte
SIRT1 decreases TP53 in mice (deacetylation following irisin-restored SIRT1).
“Further exploration revealed that irisin treatment restored sirtuin 1 (SIRT1) levels, leading to deacetylation of P53 and subsequent reduction in its expression.”
Animalsdeacetylation following irisin-restored SIRT1recombinant
“ENO2 bound GNL3 lactylated at Lys-5. This interaction displaced MDM2 from GNL3, resulting in MDM2 destabilization, impaired ubiquitination, p53 accumulation”
“RES algorithm found variations in the alignments within and across orders, suggesting that mechanisms of p53-mediated regulation of longevity may vary”
TP53 is associated with cellular senescence in silico (simulations mapping p53 dynamics).
“p 53 dynamics to fate: sustained moderate oscillations align with arrest, damped intermediate responses with senescence, and strongly damped high plateaus with apoptosis.”
TP53 is associated with cellular senescence in human cells.
“Wild type p53-GFP exclusively localized in the nuclei of growing young fibroblast, in contrast to the significant cytoplasmic retention in senescent human fibroblasts.”
TP53 is associated with DNA methylation age acceleration in humans (somatic mutation).
“variables indicating extensive genomic instability, such as TP53 somatic mutations, high tumor mutation/copy number alteration burden, and homologous repair deficiency were associated with lower DNAm AA.”
TP53 is associated with ageing gene network hub in silico (hub gene in STRING network of mouse ageing genes).
“TP53, Trp53 and Actb were identified as important genes in the network, contributing significantly to the process of ageing in humans, mice and rats, respectively”
In silicohub gene in STRING network of mouse ageing genes
TP53 is associated with ageing gene network hub in silico (hub gene in STRING network of human ageing genes).
“TP53, Trp53 and Actb were identified as important genes in the network, contributing significantly to the process of ageing in humans, mice and rats, respectively”
In silicohub gene in STRING network of human ageing genes
TP53 is associated with selection for somatic copy-number alterations in humans (TP53-mutant samples during later esophageal squamous-cell carcinoma progression).
“copy-number alterations associated with later ESCC progression were more strongly selected in TP53 -mutant samples”
HumansTP53-mutant samples during later esophageal squamous-cell carcinoma progressionesophagus
Independent labs report that TP53 shortens mouse lifespan and inhibits the senescence-associated secretory phenotype in human cells. Mouse results also include no lifespan effect; a study reports extension in Eu-myc lymphoma and LFS models. Human cell experiments report that TP53 is required for ERCC1-deficiency-induced senescence; National Institutes of Health funding is named on 94 findings.
Independent labs report TP53 shortening mouse lifespan; a mouse study reports extension in Eu-myc lymphoma and LFS models, and other mouse results include no effect. Independent labs also report TP53 suppressing the senescence-associated secretory phenotype in human cells. Authors have company affiliations in 7 of 256 findings; 6 of 193 papers declare company ties.
TP53 shortens mouse lifespan and induces animal cellular senescence across independent labs, but Δ133p53α expression extends lifespan in progeria-model mice. One group reports human associations with blood clonal expansion and, at high variant allele fractions, hematological malignancy. An author is affiliated with Golden Biotech, and a paper declares company ties.
Summary rewritten as its findings changed.
As it read before
A human study links TP53 to inferior chemotherapy outcomes in older adults with B-cell acute lymphoblastic leukemia; another links it to splenic CXCL10. One mouse-cell study shows nicotinamide mononucleotide decreases TP53; one human-cell study shows fisetin increases it.
In mice exposed to D-galactose, a hydrogen sulfide-releasing compound reduced signs of heart aging and activation of a protein involved in inflammation.In mice exposed to D-galactose, a hydrogen sulfide-releasing compound reduced signs of heart aging and activation of a protein involved in inflammation.
Experiments in mice with diabetes-induced kidney disease found less kidney tubule cell senescence, a state in which cells stop dividing, after receiving procyanidin C1.Experiments in mice with diabetes-induced kidney disease found less kidney tubule cell senescence, a state in which cells stop dividing, after receiving procyanidin C1.
In experiments in aged mice, removing the stress-response protein p53 from liver cells increased inflammation, while activating it with a drug delayed the onset of…In experiments in aged mice, removing the stress-response protein p53 from liver cells increased inflammation, while activating it with a drug delayed the onset of frailty.
Cells still stopped dividing after radiation, but protein levels changed their secreted signals and sensitivity to a drug that kills senescent cells.Cells still stopped dividing after radiation, but protein levels changed their secreted signals and sensitivity to a drug that kills senescent cells.
An analysis of breast cancer and five other cancers found mixed aging patterns, partly resembling those in normal tissue of the same origin.An analysis of breast cancer and five other cancers found mixed aging patterns, partly resembling those in normal tissue of the same origin.
Who was studiedTumors from breast and other cancers, against matched normal tissues
What changedTumors showed younger-like cell multiplication patterns but older-like damage-response and signaling patterns compared with expected tissue aging
The catchOther tumor features could explain the clock’s survival link rather than aging-related changes
An experiment in male mice with surgically induced disease compared packages released by human joint-lining stem cells from young and aged donors.An experiment in male mice with surgically induced disease compared packages released by human joint-lining stem cells from young and aged donors.